Infectious endophthalmitis after intravitreal injection of antiangiogenic agents

Teresa Diago; Colin A. McCannel; Sophie J. Bakri; Jose S. Pulido; Albert O. Edwards; John M. Pach

doi:10.1097/IAE.0b013e31819d2591

Infectious endophthalmitis after intravitreal injection of antiangiogenic agents

Teresa Diago, Colin A. McCannel, Sophie J. Bakri, Jose S. Pulido, Albert O. Edwards, John M. Pach

Ophthalmology

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Abstract

PURPOSE: To evaluate the rate of infectious endophthalmitis associated with intravitreal injection of bevacizumab, ranibizumab, and pegaptanib sodium. METHODS: A retrospective review of patients who received intravitreal injections of bevacizumab, ranibizumab, and pegaptanib sodium was undertaken. Cases of clinical diagnoses of endophthalmitis or suspected endophthalmitis resulting from intravitreal injection were identified and reviewed. From these data, the risk per injection was estimated. RESULTS: Three patients developed endophthalmitis after the intravitreal injection. The risk per injection was 0.00077 (0.077%). The rate of endophthalmitis was 1 per 1,291 injections. CONCLUSION: A similar risk of endophthalmitis per injection compared with some trials was obtained in this study. Although no definite risk factors could be identified, intravitreal injections performed by nonretina specialist physicians may be a risk factor for the development of endophthalmitis.

Original language	English (US)
Pages (from-to)	601-605
Number of pages	5
Journal	Retina
Volume	29
Issue number	5
DOIs	https://doi.org/10.1097/IAE.0b013e31819d2591
State	Published - May 2009

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/IAE.0b013e31819d2591

Cite this

@article{5a36afa697824388b19dbbbe29796c7f,

title = "Infectious endophthalmitis after intravitreal injection of antiangiogenic agents",

abstract = "PURPOSE: To evaluate the rate of infectious endophthalmitis associated with intravitreal injection of bevacizumab, ranibizumab, and pegaptanib sodium. METHODS: A retrospective review of patients who received intravitreal injections of bevacizumab, ranibizumab, and pegaptanib sodium was undertaken. Cases of clinical diagnoses of endophthalmitis or suspected endophthalmitis resulting from intravitreal injection were identified and reviewed. From these data, the risk per injection was estimated. RESULTS: Three patients developed endophthalmitis after the intravitreal injection. The risk per injection was 0.00077 (0.077%). The rate of endophthalmitis was 1 per 1,291 injections. CONCLUSION: A similar risk of endophthalmitis per injection compared with some trials was obtained in this study. Although no definite risk factors could be identified, intravitreal injections performed by nonretina specialist physicians may be a risk factor for the development of endophthalmitis.",

author = "Teresa Diago and McCannel, {Colin A.} and Bakri, {Sophie J.} and Pulido, {Jose S.} and Edwards, {Albert O.} and Pach, {John M.}",

year = "2009",

month = may,

doi = "10.1097/IAE.0b013e31819d2591",

language = "English (US)",

volume = "29",

pages = "601--605",

journal = "Retina",

issn = "0275-004X",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Infectious endophthalmitis after intravitreal injection of antiangiogenic agents

AU - Diago, Teresa

AU - McCannel, Colin A.

AU - Bakri, Sophie J.

AU - Pulido, Jose S.

AU - Edwards, Albert O.

AU - Pach, John M.

PY - 2009/5

Y1 - 2009/5

N2 - PURPOSE: To evaluate the rate of infectious endophthalmitis associated with intravitreal injection of bevacizumab, ranibizumab, and pegaptanib sodium. METHODS: A retrospective review of patients who received intravitreal injections of bevacizumab, ranibizumab, and pegaptanib sodium was undertaken. Cases of clinical diagnoses of endophthalmitis or suspected endophthalmitis resulting from intravitreal injection were identified and reviewed. From these data, the risk per injection was estimated. RESULTS: Three patients developed endophthalmitis after the intravitreal injection. The risk per injection was 0.00077 (0.077%). The rate of endophthalmitis was 1 per 1,291 injections. CONCLUSION: A similar risk of endophthalmitis per injection compared with some trials was obtained in this study. Although no definite risk factors could be identified, intravitreal injections performed by nonretina specialist physicians may be a risk factor for the development of endophthalmitis.

AB - PURPOSE: To evaluate the rate of infectious endophthalmitis associated with intravitreal injection of bevacizumab, ranibizumab, and pegaptanib sodium. METHODS: A retrospective review of patients who received intravitreal injections of bevacizumab, ranibizumab, and pegaptanib sodium was undertaken. Cases of clinical diagnoses of endophthalmitis or suspected endophthalmitis resulting from intravitreal injection were identified and reviewed. From these data, the risk per injection was estimated. RESULTS: Three patients developed endophthalmitis after the intravitreal injection. The risk per injection was 0.00077 (0.077%). The rate of endophthalmitis was 1 per 1,291 injections. CONCLUSION: A similar risk of endophthalmitis per injection compared with some trials was obtained in this study. Although no definite risk factors could be identified, intravitreal injections performed by nonretina specialist physicians may be a risk factor for the development of endophthalmitis.

UR - http://www.scopus.com/inward/record.url?scp=66349109710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349109710&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e31819d2591

DO - 10.1097/IAE.0b013e31819d2591

M3 - Article

C2 - 19357558

AN - SCOPUS:66349109710

SN - 0275-004X

VL - 29

SP - 601

EP - 605

JO - Retina

JF - Retina

IS - 5

ER -

Infectious endophthalmitis after intravitreal injection of antiangiogenic agents

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this